The Oakland-based digital health company, Eko, has developed a suite of AI-powered digital tools that allow healthcare professionals worldwide to detect and monitor heart and lung disease earlier and with higher accuracy. Its FDA-cleared technology has received over $125 million in funding from various investors, including Highland Capital Partners, Questa Capital, and Mayo Clinic. Eko's goal is to ensure that all patients have access to early heart and lung disease detection that improves and extends their lives.